Telor Ophthalmic Pharmaceuticals Inc. announced that it hasbegun Phase II clinical trials on Tekron.

The trials are designed to test the safety and efficacy ofTekron, which is a formulation of ethacrynic acid, in controllingthe elevated intraocular pressure associated with glaucoma andocular hypertension. The company (NASDAQ:TELR) is testingTekron as a once-daily topical formulation.

Telor of Woburn, Mass., has an exclusive license from theMassachusetts Eye and Ear Infirmary to patents issued in theU.S., Canada, Australia and Europe and pending elsewherecovering the use of ethacrynic acid for this purpose. The drughas already been used as a systemic for over 20 years fortreating fluid retention resulting from congestive heart failure,cirrhosis of the liver and kidney disease.

(c) 1997 American Health Consultants. All rights reserved.